SSY Group (2005) H1 2024 earnings summary

Executive summary

• Revenue for 1H2024 was HK$3,338.9 million, up 0.2% year-over-year, with net profit rising 7.4% to HK$685.7 million and EPS up 7.6% to HK$0.2312; interim dividend increased 14.3% to HK$0.08 per share.

• Growth was driven by intravenous infusion solutions and oral preparations, while ampoule injections and bulk pharmaceuticals saw revenue declines due to price pressures and refunds.

• The group maintained robust operational momentum despite a challenging economic and regulatory environment.

• The Group continued to expand its product portfolio, enhance R&D, and increase market access for new products, especially in pediatric and high-end complex generics.

Financial highlights

• Gross profit margin declined to 55.2% from 58.3% year-over-year, mainly due to higher cost of sales and a greater share of centralized procurement sales.

• Operating profit rose 7.2% to HK$849.3 million, with operating margin improving to 25.4% from 23.8% year-over-year.

• Cash and cash equivalents stood at HK$1,564.5 million as of June 30, 2024; bank borrowings increased 7.1% to HK$3,607.5 million.

• Gearing ratio increased to 22.0%, and current ratio improved to 2.63.

• Selling and distribution costs fell 17.7% to HK$758.1 million, and R&D costs slightly decreased by 1.6% to HK$136.5 million.

Outlook and guidance

• Plans to consolidate and expand product advantages, especially in infusion solutions, liquid injections, and oral preparations, and further internationalize bulk pharmaceuticals.

• Focus on high-value-added products, new product launches, and accelerating R&D innovation, with expectations to obtain approvals for 28 new products in the second half of 2024.

• Ongoing digital transformation, smart manufacturing, and infrastructure upgrades to support sustainable growth.

• Construction underway for new production lines, including PP bottle injections and double-chamber bags.